Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

被引：1

作者：

Sim, Hao-Wen

Barnes, Elizabeth

Lwin, Zarnie

Rosenthal, Mark

Wheeler, Helen

Koh, Eng-Siew

Foote, Matthew C.

Fisher, Lauren

Leonard, Robyn

Hall, Merryn

Simes, John

Khasraw, Mustafa

机构：

[1] St Vincents Hosp Sydney, Kinghorn Canc Ctr, Sydney, NSW, Australia

[2] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[3] Dept Med Oncol, Brisbane, Qld, Australia

[4] Royal Melbourne Hosp, Parkville, Vic, Australia

[5] Royal North Shore Hosp, Dept Oncol, St Leonards, NSW, Australia

[6] Liverpool Hosp, Liverpool, Merseyside, Australia

[7] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia

[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[9] COGNO Consumer Advisory Panel, Sydney, NSW, Australia

[10] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[11] Univ Sydney, Royal North Shore Hosp, St Leonards, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2042

引用

页数：2

共 50 条

[1] A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY
Khasraw, Mustafa
McDonald, Kerrie Leanne
Rosenthal, Mark
Lwin, Zarnie
Ashley, David
Wheeler, Helen
Barnes, Elizabeth
Foote, Matthew
Koh, Eng-Siew
Sulman, Erik
Back, Michael
Buckland, Michael
Sim, Hao-Wen
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Yip, Sonia
Simes, John
NEURO-ONCOLOGY, 2019, 21 : 18 - 18
[2] A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
Khasraw, Mustafa
McDonald, Kerrie Leanne
Rosenthal, Mark
Lwin, Zarnie
Ashley, David M.
Wheeler, Helen
Barnes, Elizabeth
Foote, Matthew C.
Koh, Eng-Siew
Sulman, Erik P.
Back, Michael
Buckland, Michael
Sim, Hao-Wen
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Yip, Sonia
Simes, John
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
Khasraw, Mustafa
McDonald, Kerrie Leanne
Rosenthal, Mark
Lwin, Zarnie
Ashley, David M.
Wheeler, Helen
Barnes, Elizabeth
Koh, Eng-Siew
Foote, Matthew C.
Buckland, Michael
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Yip, Sonia
Simes, John
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
Sim, Hao-Wen
McDonald, Kerrie L.
Lwin, Zarnie
Barnes, Elizabeth H.
Rosenthal, Mark
Foote, Matthew C.
Koh, Eng-Siew
Back, Michael
Wheeler, Helen
Sulman, Erik P.
Buckland, Michael E.
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Ashley, David M.
Yip, Sonia
Simes, John
Khasraw, Mustafa
NEURO-ONCOLOGY, 2021, 23 (10) : 1736 - 1749
[5] Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
Faye, Mame Daro
Easaw, Jacob
De Robles, Paula
Agnihotram, Raman
Torres-Vasquez, Alexander
Lamonde, Frederic
Petrecca, Kevin
Owen, Scott
Panet-Raymond, Valerie
Shenouda, George
Souhami, Luis
Azam, Maryam
Hossain, Bushra
Alkass, Jad
Sabri, Siham
Abdulkarim, Bassam
NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
[6] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
Athanassiou, H
Synodinou, M
Maragoudakis, E
Paraskevaidis, M
Verigos, C
Misailidou, D
Antonadou, D
Sarris, G
Beroukas, K
Karageorgis, P
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
[7] GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
Sim, Hao-Wen
Lwin, Zarnie
Barnes, Elizabeth
McDonald, Kerrie
Koh, Eng-Siew
Rosenthal, Mark
Foote, Matthew
Back, Michael
Wheeler, Helen
Buckland, Michael
Walsh, Kyle
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Ashley, David
Yip, Sonia
Simes, John
Sulman, Erik
Khasraw, Mustafa
NEURO-ONCOLOGY, 2022, 24 : 81 - 81
[8] A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Saran, Frank
James, Allan
McBain, Catherine
Jefferies, Sarah
Harris, Fiona
Cseh, Agnieszka
Pemberton, Karine
Schaible, Jennifer
Bender, Shaun
Brada, Michael
NEURO-ONCOLOGY, 2018, 20 : 20 - 20
[9] Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
Taphoorn, Martin J. B.
Henriksson, Roger
Bottomley, Andrew
Cloughesy, Timothy
Wick, Wolfgang
Mason, Warren P.
Saran, Frank
Nishikawa, Ryo
Hilton, Magalie
Theodore-Oklota, Christina
Ravelo, Arliene
Chinot, Olivier L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2166 - +
[10] Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Omuro, Antonio
Brandes, Alba A.
Carpentier, Antoine F.
Idbaih, Ahmed
Reardon, David A.
Cloughesy, Timothy
Sumrall, Ashley
Baehring, Joachim
van den Bent, Martin
Bahr, Oliver
Lombardi, Giuseppe
Mulholland, Paul
Tabatabai, Ghazaleh
Lassen, Ulrik
Sepulveda, Juan Manuel
Khasraw, Mustafa
Vauleon, Elodie
Muragaki, Yoshihiro
Di Giacomo, Anna Maria
Butowski, Nicholas
Roth, Patrick
Qian, Xiaozhong
Fu, Alex Z.
Liu, Yanfang
Potter, Von
Chalamandaris, Alexandros-Georgios
Tatsuoka, Kay
Lim, Michael
Weller, Michael
NEURO-ONCOLOGY, 2023, 25 (01) : 123 - 134

← 1 2 3 4 5 →